Neuropathy progression in Charcot-Marie-Tooth disease type 1A
Abstract
Objective: To determine the rate of disease progression in Charcot-Marie-Tooth disease type 1A (CMT1A).
Background: CMT1A is the most common inherited peripheral neuropathy, affecting approximately 1:5,000 people irrespective of ethnic background or gender. There is no cure for CMT1A. Clinical trials are being initiated that use the CMT Neuropathy Score (CMTNS), a composite score based on patient symptoms, signs, and neurophysiologic abnormalities, as the primary outcome variable. The sensitivity of the CMTNS or any other score to change over time, as a measure of CMT1A progression, has yet to be determined.
Methods: We determined the CMTNS as well as the Neuropathy Impairment Score (NIS) on 72 patients followed for up to 8 years. The rate of disease progression was evaluated for the CMTNS and NIS using mixed effects linear regression models, adjusting for age and gender.
Results: Both CMTNS and NIS showed changes over time. The CMTNS increased an average of 0.686 points per year (95% CI 0.461 to 0.911, p ≤ 0.0001). The NIS increased 1.368 points per year on average (95% CI 0.616 to 2.121, p = 0.0005). There was a suggestion that the rate of progression increased with age.
Conclusion: Progression of CMT1A can be detected by both the CMT Neuropathy Score (CMTNS) and the Neuropathy Impairment Score (NIS). This supports the feasibility of clinical trials to detect a slowing of disease progression using either or both of these scales as outcome measures. Since the CMTNS combines symptoms, signs, and electrophysiology and the NIS is based solely on the neurologic examination, the two scales may be complementary.
Get full access to this article
View all available purchase options and get full access to this article.
REFERENCES
1.
Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet 1974;6:98–118.
2.
Nelis E, Van Broeckhoven C, De Jonghe P, et al. Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet 1996;4:25–33.
3.
Lupski JR, de Oca-Luna RM, Slaugenhaupt S, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 1991;66:219–232.
4.
Raeymaekers P, Timmerman V, Nelis E, et al. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group. Neuromuscul Disord 1991;1:93–97.
5.
Thomas PK, Marques W, Davis MB, et al. The phenotypic manifestations of chromosome 17p11.2 duplication. Brain 1997;120:465–478.
6.
Krajewski KM, Lewis RA, Fuerst DR, et al. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain 2000;123:1516–1527.
7.
Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004;10:396–401.
8.
Sereda MW, Meyer Zu, Horste G, Suter U, Uzma N, Nave KA. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 2003;9:1533–1537.
9.
Meyer Zu, Horste G, Prukop T, et al. Anti-progesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Ann Neurol 2007;2007:282.
10.
Shy ME, Blake J, Krajewski K, et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 2005;64:1209–1214.
11.
Dyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O'Brien PC. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology 1995;45:1115–1121.
12.
Dyck PJ, Sherman WR, Hallcher LM, et al. Human diabetic endoneurial sorbitol, fructose, and myo-Inositol related to sural nerve morphometry. Ann Neurol 1980;8:590–596.
13.
Cohen JA, Cutter GR, Fischer JS, et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 2001;58:961–967.
14.
Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer-Verlag, 2000.
15.
Hoogendijk JE, De Visser M, Bolhuis PA, Hart AA, Ongerboer de Visser BW. Hereditary motor and sensory neuropathy type I: clinical and neurographical features of the 17p duplication subtype. Muscle Nerve 1994;17:85–90.
16.
Birouk N, Gouider R, Le Guern E, et al. Charcot-Marie-Tooth disease type 1A with 17p11.2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 cases. Brain 1997;120:813–823.
17.
Cuesta A, Pedrola L, Sevilla T, et al. The gene encoding ganglioside-induced differentiation-associated protein 1 is mutated in axonal Charcot-Marie-Tooth type 4A disease. Nat Genet 2001;30:22–25.
18.
Baxter RV, Ben Othmane K, Rochelle JM, et al. Ganglioside-induced differentiation-associated protein-1 is mutant in Charcot-Marie-Tooth disease type 4A/8q21. Nat Genet 2001;30:21–22.
19.
Zuchner S, Mersiyanova IV, Muglia M et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 2004;36:449–451.
20.
Melov S. Modeling mitochondrial function in aging neurons. Trends Neurosci 2004;27:601–606.
Information & Authors
Information
Published In
Copyright
© 2008.
Publication History
Published online: January 28, 2008
Published in print: January 29, 2008
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Clinical spectrum and frequency of Charcot–Marie–Tooth disease in Italy: Data from the National CMT Registry, European Journal of Neurology, 30, 8, (2461-2470), (2023).https://doi.org/10.1111/ene.15860
- The systemic inhibition of the terminal complement system reduces neuroinflammation but does not improve motor function in mouse models of CMT1A with overexpressed PMP22, Current Research in Neurobiology, 4, (100077), (2023).https://doi.org/10.1016/j.crneur.2023.100077
- Magnetic resonance imaging-based lower limb muscle evaluation in Charcot-Marie-Tooth disease type 1A patients and its correlation with clinical data, Scientific Reports, 12, 1, (2022).https://doi.org/10.1038/s41598-022-21112-8
- HDAC3 Inhibition Stimulates Myelination in a CMT1A Mouse Model, Molecular Neurobiology, 59, 6, (3414-3430), (2022).https://doi.org/10.1007/s12035-022-02782-x
- Candidate imaging biomarkers for PMP22 ‐related inherited neuropathies , Annals of Clinical and Translational Neurology, 9, 7, (925-935), (2022).https://doi.org/10.1002/acn3.51561
- Emerging Therapies for Charcot-Marie-Tooth Inherited Neuropathies, International Journal of Molecular Sciences, 22, 11, (6048), (2021).https://doi.org/10.3390/ijms22116048
- A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A, Orphanet Journal of Rare Diseases, 16, 1, (2021).https://doi.org/10.1186/s13023-021-02040-8
- Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis, BMC Neurology, 21, 1, (2021).https://doi.org/10.1186/s12883-021-02094-y
- Gait parameters as tools for analyzing phenotypic alterations of a mouse model of Charcot-Marie-Tooth disease, Animal Cells and Systems, 25, 1, (11-18), (2021).https://doi.org/10.1080/19768354.2021.1880967
- Intraepineurial fat quantification and cross-sectional area analysis of the sciatic nerve using MRI in Charcot-Marie-Tooth disease type 1A patients, Scientific Reports, 11, 1, (2021).https://doi.org/10.1038/s41598-021-00819-0
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.